Radforsk
Venture capital · Oslo, Norway · Europe
Radforsk is an evergreen investment company that commercialises cancer research, investing in and building biotech companies through Radforsk Invest and developing infrastructure and ecosystems through Radforsk Innovation. It also runs the Oslo Cancer Cluster, its incubator and the Oslo Cancer Cluster Innovation Park at Campus Radiumhospitalet.
Invests inHealthcare & Biotech
In its own wordsoncologybiotechimmuno-oncologyradiopharmaceuticalsprecision medicinelife sciences
Your fit with Radforsk
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsRadforsk lists 6 checked portfolio companies on its own site and is named in 1 funding round. Its most frequent entry is Series A, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 100% of its companies are based in Norway. It invests most often alongside Birk Venture, Aleap and B Capital.
Counts come from funding rounds that name Radforsk, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundRadforsk does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 100% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 1 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 8th | 6 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 89th | 17% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 20th | 1 country |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Birk Venture | 2 |
| Aleap | 1 |
| B Capital | 1 |
| F-Prime Capital | 1 |
| Farvatn Venture | 1 |
| Hadean Ventures | 1 |
| Omega Funds | 1 |
| QB Capital | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers6100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Radforsk head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Radforsk| Date | Company | Stage |
|---|---|---|
| 17 May 2026 | Series A |
Round details for Radforsk
Amounts, full round histories and every co-investor in Radforsk's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
6 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| ARTBIO develops alpha radioligand therapies for cancer treatment. | Healthcare & Biotech | Portfolio page | ||
| Ledidi provides a platform for clinical research and trials, offering data capture, statistical analytics, and global collaboration tools. | Healthcare & Biotech | May 2026Series A | Page + round | |
| Nextera is a drug and target discovery company | Healthcare & Biotech | Portfolio page | ||
| Nykode Therapeutics develops immunotherapy treatments, including a platform built around the Vaccibody molecule, to treat diseases such as cancer and autoimmune diseases. | Healthcare & Biotech | Portfolio page | ||
| Oncoinvent develops and commercializes alpha radiation therapy for cancer treatment | Healthcare & Biotech | Portfolio page | ||
| Zelluna is developing a unique and proprietary TCR-NK cell therapy platform to treat solid cancers | Healthcare & Biotech | Portfolio page |
About this data
site last read 8 Nov 2026- Site
- radforsk.com
- Last read
- 8 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 17 May 2026
- Companies checked
- 6
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Radforsk's profile as data
Pull Radforsk's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/radforsk.com
# also
GET /v1/firms/radforsk.com/portfolio
GET /v1/firms/radforsk.com/coinvestors
GET /v1/firms/radforsk.com/news